Drug side effects
crisaborole Side Effects
The reactions most often reported to the FDA for crisaborole (also sold as Eucrisa), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 9,400
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2013 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of crisaborole come from 9,400 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 9,400 reports to the FDA Adverse Event Reporting System (FAERS) for crisaborole (Eucrisa): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
9,400
Reports Mentioning Death
24
0.3% of reports — not proof the medicine caused the death
Hospitalizations
142
1.5% of reports
Top Indication
Dermatitis Atopic
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 24 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 19 |
| ACCIDENTAL DEATH | 2 |
| BURNING SENSATION | 2 |
| CONDITION AGGRAVATED | 2 |
| PRURITUS | 2 |
| ACNE | 1 |
| APPLICATION SITE PAIN | 1 |
| APPLICATION SITE PRURITUS | 1 |
| ASTHMA | 1 |
| COMA | 1 |
| DEAFNESS UNILATERAL | 1 |
| DEMENTIA | 1 |
| DRUG EFFECTIVE FOR UNAPPROVED INDICATION | 1 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 1 |
| DYSPNOEA | 1 |
| ERYTHEMA | 1 |
| INFLAMMATION | 1 |
| NEOPLASM MALIGNANT | 1 |
Reactions in Hospitalization Reports
Top reactions in 142 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ECZEMA | 22 |
| PRURITUS | 20 |
| RASH | 20 |
| FATIGUE | 18 |
| ERYTHEMA | 16 |
| CONDITION AGGRAVATED | 15 |
| ARTHRALGIA | 14 |
| DRUG HYPERSENSITIVITY | 14 |
| NASOPHARYNGITIS | 14 |
| PYREXIA | 14 |
| CHEST PAIN | 13 |
| PAIN | 13 |
| UPPER RESPIRATORY TRACT INFECTION | 13 |
| CELLULITIS | 12 |
| NAUSEA | 12 |
| PAIN IN EXTREMITY | 12 |
| URINARY TRACT INFECTION | 12 |
| HYPERSENSITIVITY | 11 |
Nearby, Related Medications
What the FAERS Data Reveals About crisaborole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 9,400 voluntary reports linked to crisaborole and its brand equivalents (Eucrisa), spanning 2013 through 2025. Of those, 24 (0.3%) listed death as an outcome and 142 (1.5%) involved hospitalization. The most common indication reported alongside adverse events was Dermatitis Atopic.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 65% were female and 35% male; age distribution skews toward 0-17, with 2,166 reports in that bracket. The single most reported reaction is application site pain with 1,415 submissions, followed by burning sensation and condition aggravated.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to crisaborole's 9,400.
Read our methodology - how this data is sourced, computed, and verified.